Cargando…
Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation
Panax ginseng, as the king of Chinese herb, has significant therapeutic effects on obesity, type 2 diabetes mellitus, fatty liver disease, colitis, diarrhea, and many other diseases. This review systematically summarized recent findings, which show that ginseng plays its role by regulating gut micro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084182/ https://www.ncbi.nlm.nih.gov/pubmed/35548468 http://dx.doi.org/10.3389/fcimb.2022.853981 |
_version_ | 1784703555893985280 |
---|---|
author | Chen, Zhaoqiang Zhang, Zepeng Liu, Jiaqi Qi, Hongyu Li, Jing Chen, Jinjin Huang, Qingxia Liu, Qing Mi, Jia Li, Xiangyan |
author_facet | Chen, Zhaoqiang Zhang, Zepeng Liu, Jiaqi Qi, Hongyu Li, Jing Chen, Jinjin Huang, Qingxia Liu, Qing Mi, Jia Li, Xiangyan |
author_sort | Chen, Zhaoqiang |
collection | PubMed |
description | Panax ginseng, as the king of Chinese herb, has significant therapeutic effects on obesity, type 2 diabetes mellitus, fatty liver disease, colitis, diarrhea, and many other diseases. This review systematically summarized recent findings, which show that ginseng plays its role by regulating gut microbiota diversity, and gut microbiota could also regulate the transformation of ginsenosides. We conclude the characteristics of ginseng in regulating gut microbiota, as the potential targets to prevent and treat metabolic diseases, colitis, neurological diseases, cancer, and other diseases. Ginseng treatment can increase some probiotics such as Bifidobacterium, Bacteroides, Verrucomicrobia, Akkermansia, and reduce pathogenic bacteria such as Deferribacters, Lactobacillus, Helicobacter against various diseases. Meanwhile, Bacteroides, Eubacterium, and Bifidobacterium were found to be the key bacteria for ginsenoside transformation in vivo. Overall, ginseng can regulate gut microbiome diversity, further affect the synthesis of secondary metabolites, as well as promote the transformation of ginsenosides for improving the absorptivity of ginsenosides. This review can provide better insight into the interaction of ginseng with gut microbiota in multiple disorders and ginsenoside transformation. |
format | Online Article Text |
id | pubmed-9084182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90841822022-05-10 Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation Chen, Zhaoqiang Zhang, Zepeng Liu, Jiaqi Qi, Hongyu Li, Jing Chen, Jinjin Huang, Qingxia Liu, Qing Mi, Jia Li, Xiangyan Front Cell Infect Microbiol Cellular and Infection Microbiology Panax ginseng, as the king of Chinese herb, has significant therapeutic effects on obesity, type 2 diabetes mellitus, fatty liver disease, colitis, diarrhea, and many other diseases. This review systematically summarized recent findings, which show that ginseng plays its role by regulating gut microbiota diversity, and gut microbiota could also regulate the transformation of ginsenosides. We conclude the characteristics of ginseng in regulating gut microbiota, as the potential targets to prevent and treat metabolic diseases, colitis, neurological diseases, cancer, and other diseases. Ginseng treatment can increase some probiotics such as Bifidobacterium, Bacteroides, Verrucomicrobia, Akkermansia, and reduce pathogenic bacteria such as Deferribacters, Lactobacillus, Helicobacter against various diseases. Meanwhile, Bacteroides, Eubacterium, and Bifidobacterium were found to be the key bacteria for ginsenoside transformation in vivo. Overall, ginseng can regulate gut microbiome diversity, further affect the synthesis of secondary metabolites, as well as promote the transformation of ginsenosides for improving the absorptivity of ginsenosides. This review can provide better insight into the interaction of ginseng with gut microbiota in multiple disorders and ginsenoside transformation. Frontiers Media S.A. 2022-04-25 /pmc/articles/PMC9084182/ /pubmed/35548468 http://dx.doi.org/10.3389/fcimb.2022.853981 Text en Copyright © 2022 Chen, Zhang, Liu, Qi, Li, Chen, Huang, Liu, Mi and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cellular and Infection Microbiology Chen, Zhaoqiang Zhang, Zepeng Liu, Jiaqi Qi, Hongyu Li, Jing Chen, Jinjin Huang, Qingxia Liu, Qing Mi, Jia Li, Xiangyan Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation |
title | Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation |
title_full | Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation |
title_fullStr | Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation |
title_full_unstemmed | Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation |
title_short | Gut Microbiota: Therapeutic Targets of Ginseng Against Multiple Disorders and Ginsenoside Transformation |
title_sort | gut microbiota: therapeutic targets of ginseng against multiple disorders and ginsenoside transformation |
topic | Cellular and Infection Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084182/ https://www.ncbi.nlm.nih.gov/pubmed/35548468 http://dx.doi.org/10.3389/fcimb.2022.853981 |
work_keys_str_mv | AT chenzhaoqiang gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT zhangzepeng gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT liujiaqi gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT qihongyu gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT lijing gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT chenjinjin gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT huangqingxia gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT liuqing gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT mijia gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation AT lixiangyan gutmicrobiotatherapeutictargetsofginsengagainstmultipledisordersandginsenosidetransformation |